3 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.2%) at 18,080 as of Tuesday, June 2, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,713 issues advancing vs. 1,260 declining with 163 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Sanofi ( SNY), up 1.2%, Novo Nordisk A/S ( NVO), up 1.1% and Perrigo ( PRGO), up 0.8%. On the negative front, top decliners within the industry include Medivation ( MDVN), down 3.1%, Vertex Pharmaceuticals ( VRTX), down 1.9%, Biogen ( BIIB), down 1.7%, Bristol-Myers Squibb Company ( BMY), down 1.3% and Incyte ( INCY), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $0.59 (1.9%) to $32.50 on light volume. Thus far, 163,629 shares of Grifols exchanged hands as compared to its average daily volume of 561,700 shares. The stock has ranged in price between $32.10-$32.69 after having opened the day at $32.10 as compared to the previous trading day's close of $31.91.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. Grifols has a market cap of $10.9 billion and is part of the health care sector. Shares are down 6.4% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Grifols a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Grifols Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Seattle Genetics ( SGEN) is up $2.39 (5.5%) to $45.78 on heavy volume. Thus far, 937,087 shares of Seattle Genetics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $42.80-$46.18 after having opened the day at $43.22 as compared to the previous trading day's close of $43.39.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes antibody-based therapies for the treatment of cancer. Seattle Genetics has a market cap of $5.4 billion and is part of the health care sector. Shares are up 35.0% year-to-date as of the close of trading on Monday. Currently there are 4 analysts who rate Seattle Genetics a buy, 2 analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Seattle Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Seattle Genetics Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Opko Health ( OPK) is up $0.43 (2.4%) to $18.74 on average volume. Thus far, 2.0 million shares of Opko Health exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $18.20-$18.88 after having opened the day at $18.21 as compared to the previous trading day's close of $18.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics. Opko Health has a market cap of $8.1 billion and is part of the health care sector. Shares are up 83.3% year-to-date as of the close of trading on Monday. Currently there are 3 analysts who rate Opko Health a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

Hologic Agrees to Sell Blood Screening Business to Grifols for $1.85B

5 Big Dividend Stocks Billionaire John Paulson Loves

5 Big Dividend Stocks Billionaire John Paulson Loves

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pulling The Health Services Industry Downward

3 Stocks Pushing The Health Services Industry Higher

3 Stocks Pushing The Health Services Industry Higher

3 Health Services Stocks Driving The Industry Higher

3 Health Services Stocks Driving The Industry Higher